Michael D. Matheson
Michael D. Matheson
(416) 863-2164
(416) 863-2653
199 Bay St, Suite 4000, Commerce Court West, Toronto, ON
Year called to bar: 1994 (ON)
Michael has more than 25 years of experience in banking and financial services law, with a particular specialization in corporate and commercial finance. His practice is focused on the areas of banking, syndicated lending, leveraged finance, project finance, and mergers & acquisitions. Michael regularly advises Canadian and foreign financial institutions and borrowers with respect to the structuring and negotiation of syndicated loan transactions, acquisition financings, takeover bid financings, leveraged buyouts, corporate reorganizations, workouts, and mergers & acquisitions. Michael is recognized as a leading lawyer in all major directories and publications.
Michael D. Matheson is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Most Frequently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Read more about Michael D. Matheson in ...
Toronto’s leading banking and finance lawyers in 2021
Lexpert reveals Toronto’s leading banking and finance lawyers based our latest peer survey
As part of the transaction, an affiliate of OMERS subscribed for an aggregate of $30 million of Dye & Durham common shares, on a private placement basis
Best asset-based lending lawyers in Canada
Lexpert reveals the best asset-based lending lawyers in Canada based on the results of our comprehensive annual peer survey
Xplornet Communications Inc., Canada's largest rural-focused broadband service provider, completed its sale to Stonepeak Infrastructure Partners
Digital Colony, the global digital infrastructure investment platform of Colony Capital, Inc., and a leading investor, owner and operator of companies enabling the next generation of mobile and Internet connectivity, acquired Beanfield Technologies Inc. (Beanfield)
Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, completed the recapitalization of approximately US$4 billion of secured and unsecured debt in September 2018 pursuant to a plan of arrangement (the “CBCA Plan”) under the Canada Business Corporations Act (“CBCA”).
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.